CASI Pharmaceuticals Reports Q3 2025 Results Amid Nasdaq Delisting Appeal

Tip Ranks
2025.11.14 22:25
portai
I'm PortAI, I can summarize articles.

CASI Pharmaceuticals reported Q3 2025 results with a 60% revenue drop to $3.1M and a net loss of $10.9M. The company is appealing a Nasdaq delisting due to market value non-compliance. Analysts rate CASI stock as a Sell with a $1.50 target, citing financial challenges and bearish trends. CASI is developing CID-103 for organ transplant rejection and autoimmune diseases.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

An update from CASI Pharmaceuticals ( (CASI) ) is now available.

On November 14, 2025, CASI Pharmaceuticals announced its third-quarter 2025 business and financial results, highlighting ongoing advancements in its CID-103 clinical program. The company is preparing for a Phase 1 study in the U.S. for renal allograft antibody-mediated rejection (AMR) and is conducting a Phase 1 study for immune thrombocytopenia (ITP). Financially, CASI reported a 60% decrease in revenue to $3.1 million compared to the previous year, primarily due to changes in the distribution agreement for EVOMELA®. The company also faced a net loss increase to $10.9 million and received a Nasdaq delisting determination due to non-compliance with market value requirements, which it is appealing.

The most recent analyst rating on (CASI) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.

Spark’s Take on CASI Stock

According to Spark, TipRanks’ AI Analyst, CASI is a Underperform.

CASI Pharmaceuticals receives a low overall stock score due to significant financial challenges, including declining revenue and high leverage. The technical analysis indicates a bearish trend, and the valuation is unattractive with a negative P/E ratio. These factors collectively contribute to the low score.

To see Spark’s full report on CASI stock, click here.

More about CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody aimed at treating organ transplant rejection and autoimmune diseases. The company holds exclusive global rights to CID-103 and is actively pursuing its development in both the U.S. and China.

Average Trading Volume: 227,975

Technical Sentiment Signal: Strong Sell

Current Market Cap: $22.46M

For an in-depth examination of CASI stock, go to TipRanks’ Overview page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.